Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection

A phase I/II study

Tze Chiang Meng, Margaret A Fischl, Ahmad M. Boota, Stephen A. Spector, Donald Bennett, Yiannis Bassiakos, Shenghan Lai, Brian Wright, Douglas D. Richman

Research output: Contribution to journalArticle

159 Citations (Scopus)

Abstract

■ Objective: To evaluate the safety and immunologic and antiviral effects of combination therapy with zidovudine and dideoxycytidine (ddC) in patients with advanced human immunodeficiency virus type 1 (HIV) infection. ■ Design: A phase I/II open-label, dose-ranging study. ■ Setting: Two AIDS Clinical Trials Group units. ■ Patients: Patients (56) with advanced HIV disease. ■ Interventions: Patients were randomly assigned to one of three paired regimens of zidovudine and ddC. We evaluated six dosing regimens, each involving oral administration of the study drugs at 8-hour intervals. ■ Measurements: Pharmacokinetics, toxicity, CD4 counts, p24 antigenemia and clinical end points. ■ Main Results: The median follow-up period was 40.6 weeks (range, 0.3 to 70 weeks). Neither drug affected the pharmacokinetic profile of the other. Episodes of serious hematologic toxicity were infrequent, occurring in only 17.9% of patients, and did not differ among the regimens (P = 0.15). Severe sensory peripheral neuropathy occurred in two patients (one patient each in regimens 1 and 4). One patient receiving regimen 4 died. The mean maximal increase in CD4 counts exceeded 109 cells/mm3, and 69% of patients receiving combinations containing 300 or 600 mg of zidovudine daily had an increase in CD4 counts of 50 cells/mm3 or greater. Regimens containing 600 mg of zidovudine daily (regimens 2 and 5) were also more likely to result in persistent increases in CD4 counts above pretreatment values than were the two lowest dose regimens (P = 0.003). The decline in CD4 counts was more rapid, and the suppression of the p24 antigenemia was less rapid and less sustained in patients receiving the lowest zidovudine dose alone (regimen 6). The addition of ddC to regimen 6 (regimen 3) resulted in a slower decline in the CD4 counts (P = 0.06). ■ Conclusions: Combination therapy with zidovudine and ddC at the doses tested was well tolerated and did not result in toxicity. A daily oral dose of 150 mg of zidovudine appeared to produce a suboptimal effect on p24 antigenemia and CD4 counts. Combination therapy with ddC and higher doses of zidovudine produced greater and more persistent effects in patients with advanced HIV infection compared with other study regimens and with the results of previous trials of zidovudine monotherapy.

Original languageEnglish
Pages (from-to)13-20
Number of pages8
JournalAnnals of Internal Medicine
Volume116
Issue number1
StatePublished - Jan 1 1992

Fingerprint

Zalcitabine
Zidovudine
Virus Diseases
HIV
CD4 Lymphocyte Count
Therapeutics
HIV-1
Pharmacokinetics
Peripheral Nervous System Diseases
Antiviral Agents
Oral Administration
Acquired Immunodeficiency Syndrome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection : A phase I/II study. / Meng, Tze Chiang; Fischl, Margaret A; Boota, Ahmad M.; Spector, Stephen A.; Bennett, Donald; Bassiakos, Yiannis; Lai, Shenghan; Wright, Brian; Richman, Douglas D.

In: Annals of Internal Medicine, Vol. 116, No. 1, 01.01.1992, p. 13-20.

Research output: Contribution to journalArticle

Meng, TC, Fischl, MA, Boota, AM, Spector, SA, Bennett, D, Bassiakos, Y, Lai, S, Wright, B & Richman, DD 1992, 'Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: A phase I/II study', Annals of Internal Medicine, vol. 116, no. 1, pp. 13-20.
Meng, Tze Chiang ; Fischl, Margaret A ; Boota, Ahmad M. ; Spector, Stephen A. ; Bennett, Donald ; Bassiakos, Yiannis ; Lai, Shenghan ; Wright, Brian ; Richman, Douglas D. / Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection : A phase I/II study. In: Annals of Internal Medicine. 1992 ; Vol. 116, No. 1. pp. 13-20.
@article{f31484d63b434ec7b7773cf1b39223cd,
title = "Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: A phase I/II study",
abstract = "■ Objective: To evaluate the safety and immunologic and antiviral effects of combination therapy with zidovudine and dideoxycytidine (ddC) in patients with advanced human immunodeficiency virus type 1 (HIV) infection. ■ Design: A phase I/II open-label, dose-ranging study. ■ Setting: Two AIDS Clinical Trials Group units. ■ Patients: Patients (56) with advanced HIV disease. ■ Interventions: Patients were randomly assigned to one of three paired regimens of zidovudine and ddC. We evaluated six dosing regimens, each involving oral administration of the study drugs at 8-hour intervals. ■ Measurements: Pharmacokinetics, toxicity, CD4 counts, p24 antigenemia and clinical end points. ■ Main Results: The median follow-up period was 40.6 weeks (range, 0.3 to 70 weeks). Neither drug affected the pharmacokinetic profile of the other. Episodes of serious hematologic toxicity were infrequent, occurring in only 17.9{\%} of patients, and did not differ among the regimens (P = 0.15). Severe sensory peripheral neuropathy occurred in two patients (one patient each in regimens 1 and 4). One patient receiving regimen 4 died. The mean maximal increase in CD4 counts exceeded 109 cells/mm3, and 69{\%} of patients receiving combinations containing 300 or 600 mg of zidovudine daily had an increase in CD4 counts of 50 cells/mm3 or greater. Regimens containing 600 mg of zidovudine daily (regimens 2 and 5) were also more likely to result in persistent increases in CD4 counts above pretreatment values than were the two lowest dose regimens (P = 0.003). The decline in CD4 counts was more rapid, and the suppression of the p24 antigenemia was less rapid and less sustained in patients receiving the lowest zidovudine dose alone (regimen 6). The addition of ddC to regimen 6 (regimen 3) resulted in a slower decline in the CD4 counts (P = 0.06). ■ Conclusions: Combination therapy with zidovudine and ddC at the doses tested was well tolerated and did not result in toxicity. A daily oral dose of 150 mg of zidovudine appeared to produce a suboptimal effect on p24 antigenemia and CD4 counts. Combination therapy with ddC and higher doses of zidovudine produced greater and more persistent effects in patients with advanced HIV infection compared with other study regimens and with the results of previous trials of zidovudine monotherapy.",
author = "Meng, {Tze Chiang} and Fischl, {Margaret A} and Boota, {Ahmad M.} and Spector, {Stephen A.} and Donald Bennett and Yiannis Bassiakos and Shenghan Lai and Brian Wright and Richman, {Douglas D.}",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "116",
pages = "13--20",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "1",

}

TY - JOUR

T1 - Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection

T2 - A phase I/II study

AU - Meng, Tze Chiang

AU - Fischl, Margaret A

AU - Boota, Ahmad M.

AU - Spector, Stephen A.

AU - Bennett, Donald

AU - Bassiakos, Yiannis

AU - Lai, Shenghan

AU - Wright, Brian

AU - Richman, Douglas D.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - ■ Objective: To evaluate the safety and immunologic and antiviral effects of combination therapy with zidovudine and dideoxycytidine (ddC) in patients with advanced human immunodeficiency virus type 1 (HIV) infection. ■ Design: A phase I/II open-label, dose-ranging study. ■ Setting: Two AIDS Clinical Trials Group units. ■ Patients: Patients (56) with advanced HIV disease. ■ Interventions: Patients were randomly assigned to one of three paired regimens of zidovudine and ddC. We evaluated six dosing regimens, each involving oral administration of the study drugs at 8-hour intervals. ■ Measurements: Pharmacokinetics, toxicity, CD4 counts, p24 antigenemia and clinical end points. ■ Main Results: The median follow-up period was 40.6 weeks (range, 0.3 to 70 weeks). Neither drug affected the pharmacokinetic profile of the other. Episodes of serious hematologic toxicity were infrequent, occurring in only 17.9% of patients, and did not differ among the regimens (P = 0.15). Severe sensory peripheral neuropathy occurred in two patients (one patient each in regimens 1 and 4). One patient receiving regimen 4 died. The mean maximal increase in CD4 counts exceeded 109 cells/mm3, and 69% of patients receiving combinations containing 300 or 600 mg of zidovudine daily had an increase in CD4 counts of 50 cells/mm3 or greater. Regimens containing 600 mg of zidovudine daily (regimens 2 and 5) were also more likely to result in persistent increases in CD4 counts above pretreatment values than were the two lowest dose regimens (P = 0.003). The decline in CD4 counts was more rapid, and the suppression of the p24 antigenemia was less rapid and less sustained in patients receiving the lowest zidovudine dose alone (regimen 6). The addition of ddC to regimen 6 (regimen 3) resulted in a slower decline in the CD4 counts (P = 0.06). ■ Conclusions: Combination therapy with zidovudine and ddC at the doses tested was well tolerated and did not result in toxicity. A daily oral dose of 150 mg of zidovudine appeared to produce a suboptimal effect on p24 antigenemia and CD4 counts. Combination therapy with ddC and higher doses of zidovudine produced greater and more persistent effects in patients with advanced HIV infection compared with other study regimens and with the results of previous trials of zidovudine monotherapy.

AB - ■ Objective: To evaluate the safety and immunologic and antiviral effects of combination therapy with zidovudine and dideoxycytidine (ddC) in patients with advanced human immunodeficiency virus type 1 (HIV) infection. ■ Design: A phase I/II open-label, dose-ranging study. ■ Setting: Two AIDS Clinical Trials Group units. ■ Patients: Patients (56) with advanced HIV disease. ■ Interventions: Patients were randomly assigned to one of three paired regimens of zidovudine and ddC. We evaluated six dosing regimens, each involving oral administration of the study drugs at 8-hour intervals. ■ Measurements: Pharmacokinetics, toxicity, CD4 counts, p24 antigenemia and clinical end points. ■ Main Results: The median follow-up period was 40.6 weeks (range, 0.3 to 70 weeks). Neither drug affected the pharmacokinetic profile of the other. Episodes of serious hematologic toxicity were infrequent, occurring in only 17.9% of patients, and did not differ among the regimens (P = 0.15). Severe sensory peripheral neuropathy occurred in two patients (one patient each in regimens 1 and 4). One patient receiving regimen 4 died. The mean maximal increase in CD4 counts exceeded 109 cells/mm3, and 69% of patients receiving combinations containing 300 or 600 mg of zidovudine daily had an increase in CD4 counts of 50 cells/mm3 or greater. Regimens containing 600 mg of zidovudine daily (regimens 2 and 5) were also more likely to result in persistent increases in CD4 counts above pretreatment values than were the two lowest dose regimens (P = 0.003). The decline in CD4 counts was more rapid, and the suppression of the p24 antigenemia was less rapid and less sustained in patients receiving the lowest zidovudine dose alone (regimen 6). The addition of ddC to regimen 6 (regimen 3) resulted in a slower decline in the CD4 counts (P = 0.06). ■ Conclusions: Combination therapy with zidovudine and ddC at the doses tested was well tolerated and did not result in toxicity. A daily oral dose of 150 mg of zidovudine appeared to produce a suboptimal effect on p24 antigenemia and CD4 counts. Combination therapy with ddC and higher doses of zidovudine produced greater and more persistent effects in patients with advanced HIV infection compared with other study regimens and with the results of previous trials of zidovudine monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0026513969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026513969&partnerID=8YFLogxK

M3 - Article

VL - 116

SP - 13

EP - 20

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 1

ER -